Identification and Validation of Prognostic Signature of Papillary Thyroid Carcinoma Based on Six Immune‐Related lncRNAs
Biotechnology and Applied Biochemistry · 2025
DOI: 10.1002/bab.70063 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Biotechnology and Applied Biochemistry, 2025. Verfasst von Xuelei Zhu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, The People's Hospital of Nanchuan, Chongqing, China. Hauptthemen laut MEDLINE: RNA, Long Noncoding, Thyroid Cancer, Papillary, Thyroid Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Abstract (Originalsprache)
This research seeks to identify and verify the prognostic signature of immune‐related RNA of papillary thyroid carcinoma (PTC). The Cancer Genome Atlas (TCGA) database provided the PTC samples and clinical data. Using the limma program, differentially expressed mRNAs and lncRNAs (DElncRNAs) were found. A risk score (RS) model was created by using univariate and multivariate Cox regression analyses to find lncRNAs associated with overall survival prognosis. The association between the lncRNA prognostic signature and the invasion of several immune cell subtypes was investigated using the Tumor Immune Estimation Resource (TIMER). To verify the expression of the prognostic signature, RT‐PCR was utilized. From TCGA, 491 PTC tumor samples were acquired, comprising 18497 mRNAs and 2525 lncRNAs. There were 138 DElncRNAs and 494 differentially expressed mRNAs. Six DElncRNAs with independent prognoses were then selected from a total of 138 DElncRNAs. According to the TIMER database, the 6‐DElncRNA PTC prognostic signature was correlated with the invasion of several immune cell subtypes. The expression patterns of four DElncRNAs matched the database results, according to RT‐PCR analysis. Six lncRNAs were found to constitute a predictive characteristic for PTC in this study, and these signatures were connected to the infiltration of different immune cell subtypes. These findings provide a potential basis for the development of diagnostic biomarkers and immunotherapeutic stratification in PTC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, The People's Hospital of Nanchuan, Chongqing, China.
ORCID-Profile: Xuelei Zhu
Zitieren
APA
Zhu, X., Luo, Y., Zhang, Y., Zhou, H., Xiang, J., Su, Y., & Chen, L. (2025). Identification and Validation of Prognostic Signature of Papillary Thyroid Carcinoma Based on Six Immune‐Related lncRNAs. Biotechnology and Applied Biochemistry. https://doi.org/10.1002/bab.70063
Vancouver
Zhu X, Luo Y, Zhang Y, Zhou H, Xiang J, Su Y, et al. Identification and Validation of Prognostic Signature of Papillary Thyroid Carcinoma Based on Six Immune‐Related lncRNAs. Biotechnology and Applied Biochemistry. 2025. doi:10.1002/bab.70063
BibTeX
@article{Zhu2025,
author = {Zhu, Xuelei and Luo, Yan and Zhang, Yi and Zhou, Huamei and Xiang, Jiao and Su, Yunhua and Chen, Lijing},
title = {Identification and Validation of Prognostic Signature of Papillary Thyroid Carcinoma Based on Six Immune‐Related lncRNAs},
journal = {Biotechnology and Applied Biochemistry},
year = {2025},
doi = {10.1002/bab.70063}
}
EUVIMED